Independent Investment Research · Free insights
U.S. companies. Clear investment insights.
Start with U.S. company news, technology and biotechnology. Explore credit and alternatives, with Australian markets and fund charts further below.
September & October 2026 editions
Read our latest newsletters
The latest LMI Monthly, U.S. Biotechnology and Technology editions lead the list, followed by Metals & Mining and earlier editions. Free editions are open to everyone; the U.S. Biotechnology research issue requires professional access.
- Listed funds · September dataIIR LMI Monthly Update — 15 October 2026 · Free newsletter · 35 pages
- October 2026U.S. BiotechnologyMovers & Shakers — Issue No. 3 · Professional access
- U.S. TechnologyMovers & Shakers — US Micro-Cap Technology, Issue No. 2: The Index Is Not the Population · Free newsletter
- Metals & MiningMovers & Shakers: From Orebody to Shareholder · Free newsletter
- Listed funds · August dataIIR LMI Monthly Update — 3 October 2026 · Free newsletter
- U.S. TechnologyMovers & Shakers: From Adoption to Cash
- AlternativesSeptember Alternatives Monitor: Beyond the wrapper
- Metals & MiningMovers & Shakers: From Promise to Proof
- September 2026U.S. BiotechnologyMovers & Shakers — Issue No. 2 · Professional access
News and announcements
U.S. company announcements
Announcement dates shown. Each brief links to its original sources.
- Nasdaq: ACXPAcurx reports first patient enrolment in PATHFINDER
- Nasdaq: PRGSProgress revenue declines as earnings and cash flow improve
- Nasdaq: ACXPAcurx reports laboratory findings ahead of planned patient trials
- Nasdaq: DAKTDaktronics sales rise while new orders decline
- OTCQB: BIXTBioxytran reports an early observation from one patient
Sector guides
US biotech
Start with the sector, then explore trial results and the cash needed to reach the next milestone.
US biotech: the science, the milestones and the money
A clear way to read drug-development headlines: connect the evidence, the FDA decision and the cash needed to reach the next milestone.
Read the articleHow to read a biotech trial result beyond the headline
Start with the planned question, then examine the size of the result, its uncertainty and the safety findings.
Read the articleBiotech cash runway: what the next milestone actually costs
A simple months-of-cash figure can miss one-off costs, repayment dates and the spending needed after a trial result.
Read the articleCredit & income
Credit funds
Start with U.S. listed credit funds, then explore cash income, liquidity and Australian credit-fund research.
Reading US credit funds: Ares Capital and BXSL explained
Two listed lenders show why portfolio quality, issuer creditworthiness and investor liquidity need separate questions.
Read the articleCredit fund income: how much arrives as cash?
Follow the money from borrower interest to investor distributions, with a simple example of cash income, PIK and costs.
Read the articleCredit fund liquidity: when can you get your money back?
Selling listed units, asking for a withdrawal and accepting a repurchase offer are different ways to exit. Timing and price matter in each.
Read the articleAustralian credit funds: read the rating, then read the risks
A dated assessment of Metrics Income Opportunities Trust shows why the rating, underlying loans and access to your money deserve separate questions.
Read the articleAustralian markets
Australian company & fund updates
Announcement dates shown. Listed fund charts follow below.
July & August 2026 snapshots
Listed funds, in three charts
Price and pre-tax NTA at 31 July; fund size and monthly returns at 31 August. Historical snapshots with sources and sample notes.
Start with the essentials
Investing basics
Short guides to fund structures, asset values and the numbers behind a factsheet. No account needed.
LIC, LIT or ETF: what changes?
All three can put a portfolio within reach through one exchange trade. Their structures work differently.
Read the guideWhat does NTA actually tell you?
A short guide to the asset figure behind a listed investment company or trust.
Read the guideWhy can the price differ from the assets?
A premium or discount describes a gap. Understanding the gap takes another step.
Read the guideIncome and total return: what is the difference?
A payment into your account is only one part of the result. The value of what you still own matters too.
Read the guideHow to read a fund factsheet
Start with what the fund does, then put its performance, costs and holdings into context.
Read the guideWhy the dates on investment data matter
The date a number describes can be different from the day it reaches your screen.
Read the guide